Analysis on survival and prognostic factors in patients with resectable pancreatic adenocarcinoma

Abstract

Survival after pancreatic cancer surgery is extremely unfavorable even after curative resection. Prognostic factors have been explored but remain largely undefined. The present study was to identify the role of clinical and laboratory variables in the prognostic significance of resectable pancreatic adenocarcinoma. A total of 96 patients who underwent curative resection for pancreatic cancer were included. Survival was evaluated based on complete follow-up visits and was associated with potential prognostic factors using the Kaplan-Meier method and Cox proportional hazard model survival analyses. The results showed that prognostic variables significantly reduced survival, including old age, poorly differentiated tumors, elevated tumor markers and positive lymph node metastasis (LNM). Age of older than 60 years (HR=1.83, P=0.04), LNM (HR=2.22, P=0.01), lymph node ratio (0<LNR≤0.2, HR=1.38, P=0.042; LNR>0.2, HR=1.92, P=0.017), initial CA199 (HR=4.80, P=0.004), and CEA level (HR=2.59, P=0.019) were identified as independent prognostic factors by multivariate analysis. It was concluded that LNR may be potent predictor of survival and suggests that surgeons and the pathologists should thoroughly assess lymph nodes prior to surgery.

Keywords

pancreatic adenocarcinoma / survival / prognosis / lymph node ratio

References

[1] SiegelR, MaJ, ZouZ, et al. . Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1): 9-29 PMID: 24399786

[2] RahibL, SmithBD, AizenbergR, et al. . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res, 2014, 74(11): 2913-2921 PMID: 24840647

[3] SunH, MaH, HongG, et al. . Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981-2010. Sci Rep, 2014, 4: 6747 PMID: 25339498 PMCID: 5381379

[4] DuL, DeFoeM, RuzinovaMB, et al. . Perioperative therapy for surgically resectable pancreatic adenocarcinoma. Hematol Oncol Clin North Am, 2015, 29(4): 717-726 PMID: 26226906 PMCID: 4699862

[5] WrayCJ, AhmadSA, MatthewsJB, et al. . Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology, 2005, 128(6): 1626-1641 PMID: 15887155

[6] StojadinovicA, BrooksA, HoosA, et al. . An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J Am Coll Surg, 2003, 196(6): 954-964 PMID: 12788434

[7] YamamotoY, IkomaH, MorimuraR, et al. . The clinical impact of the lymph node ratio as a prognostic factor after resection of pancreatic cancer. Anticancer research, 2014, 34(5): 2389-2394 PMID: 24778048

[8] BenassaiG, QuartoG, PerrottaS, et al. . Long-term survival after curative resection for pancreatic ductal adenocarcinoma-Surgical treatment. Int J Surg, 2015, 21: S1-3 PMID: 26118618

[9] YamamotoT, YagiS, KinoshitaH, et al. . Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis. World J Gastroenterol, 2015, 21(1): 262-268 PMID: 25574100 PMCID: 4284344

[10] LiD, ChenC, ZhouY, et al. . Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Medicine, 2015, 94(35): 1345

[11] SchwarzRE, SmithDD. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol, 2006, 13(9): 1189-1200 PMID: 16955385

[12] FujiiT. Extended lymphadenectomy in pancreatic cancer is crucial. World J Surg, 2013, 37(8): 1778-1781 PMID: 23568249

[13] MarmorS, BurkeEE, PortschyPR, et al. . Lymph node evaluation for treatment of adenocarcinoma of the pancreas. Surg Oncol, 2015, 24(3): 284-291 PMID: 26303825

[14] DasariBV, PasqualiS, VohraRS, et al. . Extended versus standard lymphadenectomy for pancreatic head cancer: Meta-analysis of randomized controlled trials. J Gastrointest Surg, 2015, 19(9): 1725-1732 PMID: 26055135

[15] JangJY, KangMJ, HeoJS, et al. . A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg, 2014, 259(4): 656-664 PMID: 24368638

[16] PelucchiC, GaleoneC, PoleselJ, et al. . Smoking and body mass index and survival in pancreatic cancer patients. Pancreas, 2014, 43(1): 47-52 PMID: 24177141

[17] GaujouxS, TorresJ, OlsonS, et al. . Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg Oncol, 2012, 19(9): 2908-2916 PMID: 22411205

[18] DandonaM, LinehanD, HawkinsW, et al. . Influence of obesity and other risk factors on survival outcomes in patients undergoing pancreaticoduodenectomy for pancreatic cancer. Pancreas, 2011, 40(6): 931-937 PMID: 21747317

[19] TramacereI, ScottiL, JenabM, et al. . Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int J Cancer, 2010, 126(6): 1474-1486 PMID: 19816941

[20] OlsonSH, ChouJF, LudwigE, et al. . Allergies, obesity, other risk factors and survival from pancreatic cancer. Int J Cancer, 2010, 127(10): 2412-2419 PMID: 20143395

[21] ParkSM, LimMK, ShinSA, et al. . Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol, 2006, 24(31): 5017-5024 PMID: 17075121

[22] MiuraJT, KreplineAN, GeorgeB, et al. . Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Surgery, 2015, 158(6): 1545-1555 PMID: 26243342

[23] BolmL, JanssenS, KasmannL, et al. . Predicting survival after irradiation of metastases from pancreatic cancer. Anticancer Res, 2015, 35(7): 4105-4108 PMID: 26124362

[24] YangX, HaoJ, ZhuCH, et al. . Survival benefits of western and traditional Chinese Medicine treatment for patients with pancreatic cancer. Medicine, 2015, 94(26): 1008

[25] TanakaT, IkedaM, OkusakaT, et al. . Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol, 2008, 38(11): 755-761 PMID: 18845521

[26] BilimoriaKY, BentremDJ, KoCY, et al. . Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer, 2007, 110(4): 738-744 PMID: 17580363

[27] FischerLK, KatzMH, LeeSM, et al. . The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. Histopathology, 2016, 68(2): 210-220 PMID: 25945396

[28] ZhouD, YeM, BaiY, et al. . Prognostic value of lymph node ratio in survival of patients with locally advanced rectal cancer. Can J Surg, 2015, 58(4): 237-244 PMID: 26022151 PMCID: 4512865

[29] ZhaoBW, ChenYM, JiangSS, et al. . Lymph node metastasis, a unique independent prognostic factor in early gastric cancer. PLoS One, 2015, 10(7): 0129531

[30] YooT, LeeWJ, WooSM, et al. . Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys, 2011, 81(4): 623-630

[31] ChenY, GaoSG, ChenJM, et al. . Serum CA242, CA199, CA125, CEA, and TSGF are biomarkers for the efficacy and prognosis of cryoablation in pancreatic cancer patients. Cell Biochem Biophys, 2015, 71(3): 1287-1291 PMID: 25486903

[32] O’BrienDP, SandanayakeNS, JenkinsonC, et al. . Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res, 2015, 21(3): 622-631 PMID: 24938522

[33] TasF, KarabulutS, CiftciR, et al. . Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Cancer Chemother Pharmacol, 2014, 73(6): 1163-1171 PMID: 24647734

[34] LagergrenJ, MattssonF, ZylstraJ, et al. . Extent of lymphadenectomy and prognosis after esophageal cancer surgery. JAMA Surg, 2016, 151(1): 32-39 PMID: 26331431

[35] NimuraY, NaginoM, TakaoS, et al. . Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci, 2012, 19(3): 230-241 PMID: 22038501

[36] ChiangKC, YehCN, UengSH, et al. . Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer. World J Surg Oncol, 2012, 10: 77 PMID: 22559838 PMCID: 3488570

[37] Uson JuniorPL, FrancaMS, RodriguesHV, et al. . Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered. Einstein (Sao Paulo), 2015, 13(3): 347-351

[38] YoonKW, HeoJS, ChoiDW, et al. . Factors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma. J Korean Surg Soc, 2011, 81(6): 394-401 PMID: 22200040 PMCID: 3243856

[39] LeeSR, KimHO, SonBH, et al. . Prognostic factors associated with long-term survival and recurrence in pancreatic adenocarcinoma. Hepatogastroenterology, 2013, 60(122): 358-362 PMID: 23574658

[40] EngelkenFJ, BettschartV, RahmanMQ, et al. . Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol, 2003, 29(4): 368-373 PMID: 12711291

[41] KrishnanS, RanaV, JanjanNA, et al. . Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer, 2006, 107(11): 2589-2596 PMID: 17083124